Does addition of Tazarotene cream help in controlling fungal infections of skin over and above two antifungal medicines?

Does addition of tazarotene to standard antifungals aid in controlling Tinea infections? An add on trial over topical luliconazole and oral terbinafine

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/09/021049

Enrollment

Registered

2019-09-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B354- Tinea corporis

Interventions

Intervention1: Topical Tazarotene, Topical Luliconazole and Terbinafine tablet: Topical Tazarotene 0.1% cream twice daily, Topical Luliconazole 1% cream twice daily and Terbinafine 250 mg tablet twice

Eligibility

Inclusion criteria

Inclusion criteria: Untreated male and non-Â¬pregnant female patients above 18 years of age; Acute, symptomatic tinea cruris/corporis with limited involvement i.e. limited to single body region; KOH mount showing positive results (hyphae)

Exclusion criteria

Exclusion criteria: Pregnant or nursing females; Patients with diabetes mellitus, malignancy, renal or hepatic dysfunction; Patients who received topical antifungal agents within the past week or received systemic antifungal agents within past four weeks; History of hypersensitivity to any of the study drugs; Patients not willing to comply with protocol requirements

Design outcomes

Primary

Measure	Time frame
100% Clinical cure (Disappearance of original lesions with or without residual pigmentation)Timepoint: 4th week and 6th week	—

Secondary

Measure	Time frame
Compliance measured by receiving empty strips and tubes of drugs givenTimepoint: 2nd, 4th, 6th week;Global cure (combined mycological and clinical cure)Timepoint: 6th week;Mycological cure defined as negative KOH microscopy and negative cultureTimepoint: 4th week and 6th week;Quality of life assessed by using vernacular version of Dermatology Life Quality Index (DLQI).Timepoint: baseline, 6th week;Safety parameter: Routine laboratory investigations: Routine hemogram, random blood sugar, urea, creatinine, liver function tests (LFT).Timepoint: Baseline, 4th week;Grade of clinical improvement: o Grade 0 (Clinical Failure): No improvement. o Grade I: Persistence of few papular lesions or erythema with mild to moderate itching. o Grade II: Scaly lesions with or without itching. o Grade III (Clinical cure): Disappearance of original lesions with or without residual pigmentationTimepoint: 2nd, 4th, 6th week;Safety parameter: Spontaneously reported adverse events and those elicited by the clinicianTimepoint: 2nd, 4th, 6th week	—

Measure

Time frame

Compliance measured by receiving empty strips and tubes of drugs givenTimepoint: 2nd, 4th, 6th week;Global cure (combined mycological and clinical cure)Timepoint: 6th week;Mycological cure defined as negative KOH microscopy and negative cultureTimepoint: 4th week and 6th week;Quality of life assessed by using vernacular version of Dermatology Life Quality Index (DLQI).Timepoint: baseline, 6th week;Safety parameter: Routine laboratory investigations: Routine hemogram, random blood sugar, urea, creatinine, liver function tests (LFT).Timepoint: Baseline, 4th week;Grade of clinical improvement: o Grade 0 (Clinical Failure): No improvement. o Grade I: Persistence of few papular lesions or erythema with mild to moderate itching. o Grade II: Scaly lesions with or without itching. o Grade III (Clinical cure): Disappearance of original lesions with or without residual pigmentationTimepoint: 2nd, 4th, 6th week;Safety parameter: Spontaneously reported adverse events and those elicited by the clinicianTimepoint: 2nd, 4th, 6th week

—

Countries

India

Contacts

Public ContactAmrita Sil

Bankura Sammilani Medical College

drdasnilay@gmail.com9433394148

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026